SOURCE: Rheologics Technologies, Inc.

January 26, 2007 23:08 ET

Rheologics Announces Phase I Clinical Study on Blood Viscosity and Peripheral Vascular Disease

EXTON, PA -- (MARKET WIRE) -- January 26, 2007 -- Rheologics, Inc., a subsidiary of Rheologics Technologies, Inc. (PINKSHEETS: RTGI) ("Rheologics"), today announced the initiation of a Phase I study to explore the effect of lowering blood viscosity in patients with critical limb ischemia and end-stage peripheral vascular disease. The study is taking place at the Seoul Veterans Hospital in Seoul, South Korea utilizing the Rheolog® blood viscometer.

Peripheral vascular disease, or peripheral arterial disease ("PAD"), is a form of atherosclerosis that occurs in the lower extremities and affects 1 in 20 people over the age of 50, between 8 to 12 million people in the United States. There are approximately 63 million patients affected by PAD in developed countries worldwide. Approximately 31 million of the affected population are symptomatic and about 7.5 million of those require treatment. PAD is the cause of over 100,000 lower extremity amputations in the U.S. every year.

The Phase I study will include patients divided into 2 groups on the basis of a randomized controlled trial: patients in the control group receiving conventional treatment and patients receiving treatment to lower blood viscosity. The objective is to evaluate the effect of blood viscosity reduction in end-stage PAD resistant to maximal medical therapy and where revascularization therapy (both percutaneous and surgical) has either proved insufficient or is contra-indicated or declined by the patient, usually resulting in amputation. The primary outcome parameters will be the salvage rate of the limb as compared with the salvage rate of the limb with conventional therapy.

Kenneth R. Kensey, MD, Chief Scientific Officer of Rheologics, said, "Whole blood viscosity is the parameter that best quantifies the injurious characteristics of blood flow. Since the blood pressure in the legs is typically three times greater than the blood pressure in the arms due to the pulling force of gravity, we have good reason to believe that blood flow, especially highly viscous and injurious blood flow, is the true culprit behind PAD. Leg amputation because of PAD is devastating for each and every patient. If by lowering blood viscosity, we can improve the limb salvage rate of end-stage PAD patients, we will have made a major contribution to the quality of millions of lives around the world."

The Rheolog® is an FDA IDE-exempt device approved for research and for providing additional information in the interpretation of disease.

About Rheologics Technologies, Inc.

Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventative diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.

Contact Information